HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone (amino acids 176-191). This 16-amino-acid fragment retains the lipolytic activity of full-length growth hormone while lacking its somatotropic (growth-promoting) and diabetogenic effects. Research into this fragment illuminates the structural basis of growth hormone’s metabolic functions and provides a tool for studying fat metabolism independent of IGF-1 signaling.
Structural Context
Human growth hormone (hGH) is a 191-amino-acid protein that exerts diverse metabolic effects through the growth hormone receptor (GHR). The biological activities of hGH can be mapped to different structural regions. The N-terminal and central domains are primarily responsible for GHR binding and activation, which drives IGF-1 production, linear growth, and anabolic effects. The C-terminal region (amino acids 176-191) forms a loop structure stabilized by a disulfide bond between Cys182 and Cys189 and is responsible for the fat-metabolizing activity of hGH.
Fragment 176-191 was identified through systematic truncation studies by the Monash University group. When the C-terminal region was synthesized independently, it demonstrated lipolytic activity in adipocyte assays without activating the GHR-JAK2-STAT5 signaling pathway responsible for growth and IGF-1 production. This separation of metabolic from growth-promoting activities was the key finding driving further research.
Mechanism of Action
Fragment 176-191 stimulates lipolysis (fat breakdown) through a mechanism distinct from full-length GH. While hGH promotes lipolysis primarily through GHR-mediated signaling, the fragment appears to interact with a different, as-yet-uncharacterized binding site or receptor on adipocyte membranes. Studies suggest involvement of beta-3 adrenergic receptor signaling, with the fragment enhancing hormone-sensitive lipase (HSL) phosphorylation and activity.
The fragment also inhibits lipogenesis (fat synthesis) by reducing expression of key lipogenic enzymes including fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). In adipocyte cultures, Fragment 176-191 treatment reduced de novo fatty acid synthesis by 40-60% at effective concentrations, comparable to the lipogenesis-inhibiting effect of full-length GH.
Importantly, Fragment 176-191 does not affect glucose homeostasis in the way full-length GH does. GH administration causes insulin resistance through multiple mechanisms, but the fragment shows no effect on insulin sensitivity, glucose uptake, or hepatic glucose output in preclinical studies. This metabolic selectivity is a direct consequence of the fragment’s inability to activate the GHR.
Preclinical Evidence
In obese mouse models (ob/ob mice), Fragment 176-191 administration reduced body weight and fat mass without affecting lean mass, food intake, or IGF-1 levels. The selectivity for fat reduction without growth effects was confirmed through body composition analysis showing decreased white adipose tissue weight without changes in organ weights, bone length, or muscle mass.
Adipocyte-level studies revealed dose-dependent lipolysis enhancement, with maximal effects at concentrations comparable to physiological GH levels. The fragment’s effects were additive with catecholamine-stimulated lipolysis, suggesting it engages a parallel pathway rather than amplifying beta-adrenergic signaling.
Relationship to AOD-9604
AOD-9604 is a modified version of Fragment 176-191 with an additional tyrosine residue appended at the C-terminus (position 177 of the native hGH sequence is also included). This modification was introduced to improve the peptide’s stability and potentially enhance its bioactivity. AOD-9604 progressed further in clinical development, reaching Phase 2 trials for obesity, whereas Fragment 176-191 remains primarily a research tool.
Research Applications
Fragment 176-191 serves as a valuable research tool for dissecting growth hormone biology. Its ability to isolate the lipolytic function from other GH activities enables mechanistic studies of fat metabolism that would be confounded by the pleiotropic effects of full-length GH. Researchers use it to study adipocyte signaling pathways, lipid metabolism regulation, and the structural determinants of GH bioactivity.
Frequently Asked Questions
What is HGH Fragment 176-191?
It is a synthetic peptide corresponding to amino acids 176-191 of human growth hormone, studied for its lipolytic properties without the growth-promoting effects of full-length HGH.
How does HGH Frag differ from full HGH?
It does not bind the classical GH receptor, does not stimulate IGF-1 production or tissue growth, and does not cause insulin resistance. It specifically targets fat metabolism through beta-3 adrenergic pathways.
What is the difference between HGH Frag 176-191 and AOD-9604?
AOD-9604 is a modified version with an additional tyrosine residue for improved stability. AOD-9604 has more clinical trial data, while HGH Frag 176-191 is used primarily as a research tool.